Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: A randomized, placebo-controlled clinical trial

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 2, 2009, Pages 469-476

  Aroda, Vanita R ^a,b,c   Ciaraldi, Theodore P ^a,b   Burke, Paivi ^a   Mudaliar, Sunder ^a,b   Clopton, Paul ^a   Phillips, Susan ^a,b   Chang, R Jeffrey ^d   Henry, Robert R ^a,b  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c MEDSTAR RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANDROGEN; HYDROXYPROGESTERONE; INSULIN; LEUPRORELIN; PIOGLITAZONE; PLACEBO;

ADULT; ANDROGEN SYNTHESIS; ANTHROPOMETRY; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLUCOSE TOLERANCE; HORMONE ACTION; HUMAN; HYPERINSULINEMIA; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 59749094101     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-1133     Document Type: Article

References (34)

1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO 2004 The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89:2745-2749
2. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R 1998 Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 83:3078-3082
3. Legro RS, Kunselman AR, Dodson WC, Dunaif A 1999 Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84:165-169
4. Dunaif A, Segal KR, Futterweit W, Dobrjansky A 1989 Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38:1165-1174
5. Ek I, Arner P, Bergqvist A, Carlström K, Wahrenberg H 1997 Impaired adipocyte lipolysis in nonobese women with the polycystic ovary syndrome: a possible link to insulin resistance? J Clin Endocrinol Metab 82:1147-1153
6. Sepilian V, Nagamani M 2005 Adiponectin levels in women with polycystic ovary syndrome and severe insulin resistance. J Soc Gynecol Investig 12:129-134
7. Sieminska L, Marek B, Kos-Kudla B, Niedziolka D, Kajdaniuk D, Nowak M, Glogowska-Szelag J 2004 Serum adiponectin in women with polycystic ovarian syndrome and its relation to clinical, metabolic and endocrine parameters. J Endocrinol Invest 27:528-534
8. Aroda V, Ciaraldi TP, Chang SA, Dahan MH, Chang RJ, Henry RR 2008 Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action. Fertil Steril 89:1200-1208
9. Rosenfield RL, Barnes RB, Ehrmann DA 1994 Studies of the nature of 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism. J Clin Endocrinol Metab 79:1686-1692
10. Ehrmann DA, Rosenfield RL, Barnes RB, Brigell DF, Sheikh Z 1992 Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med 327:157-162
11. Nahum R, Thong KJ, Hillier SG 1995 Metabolic regulation of androgen production by human thecal cells in vitro. Hum Reprod 10:75-81
12. Zawadzki JK, Dunaif A 1992 Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, eds. Polycystic ovary syndrome. Oxford, UK: Blackwell; 59-69
13. Fauser BC, Van Heusden AM 1997 Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocr Rev 18:71-106
14. DeFronzo RA, Tobin JD, Andres R 1979 Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223
15. Mudaliar S, Mohideen P, Deutsch R, Ciaraldi TP, Armstrong D, Kim B, Sha X, Henry RR 2002 Intravenous glargine and regular insulin have similar effects on endogenous glucose output and peripheral activation/deactivation kinetic profiles. Diabetes Care 25:1597-1602
16. Thorburn AW, Gumbiner B, Bulacan F, Wallace P, Henry RR 1990 Intracellular glucose oxidation and glycogen synthase activity are reduced in noninsulin-dependent (type II) diabetes independent of impaired glucose uptake. J Clin Invest 85:522-529
17. Mather KJ, Funahashi T, Matsuzawa Y, Edelstein S, Bray GA, Kahn SE, Crandall J, Marcovina S, Goldstein B, Goldberg R 2008 Diabetes prevention program adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. Diabetes 57:980-986
18. Majuri A, Santaniemi M, Rautio K, Kunnari A, Vartiainen J, Ruokonen A, Kesäniemi YA, Tapanainen JS, Ukkola O, Morin-Papunen L 2007 Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study. Eur J Endocrinol 156:263-269
19. Imatoh T, Miyazaki M, Momose Y, Tanihara S, Une H 2008 Adiponectin levels associated with the development of hypertension: a prospective study. Hypertens Res 31:229-233
20. Chow WS, Cheung BM, Tso AW, Xu A, Wat NM, Fong CH, Ong LH, Tam S, Tan KC, Janus ED, Lam TH, Lam KS 2007 Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. Hypertension 49:1455-1461
21. Laughlin GA, Barrett-Connor E, May S, Langenberg C 2007 Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study. Am J Epidemiol 165:164-174
22. Shadid S, Stehouwer CD, Jensen MD 2006 Diet/exercise versus pioglitazone: effects of insulin sensitization with decreasing or increasing fat mass on adipokines and inflammatory markers. J Clin Endocrinol Metab 91:3418-3425
23. Arlt W, Auchus RJ, Miller WL 2001 Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes p450c17 and 3b-hydroxysteroid dehydrogenase. J Biol Chem 276:16767-16771
24. Gasic S, Nagamani M, Green A, Urban RJ 2001 Troglitazone is a competitive inhibitor of 3β-hydroxysteroid dehydrogenase enzyme in the ovary. Am J Obstet Gynecol 184:575-579
25. Kempná P, Hofer G, Mullis PE, Flück CE 2006 Pioglitazone inhibits androgen production in NCI-H295R cells by regulating gene expression of CYP17 and HSD3B2. Mol Pharmacol 71:787-798
26. Qin KN, Rosenfield RL 1998 Role of cytochrome P450c17 in polycystic ovary syndrome. Mol Cell Endocrinol 145:111-121
27. Munir I, Yen HW, Geller DH, Torbati D, Bierden RM, Weitsman SR, Agarwal SK, Magoffin DA 2004 Insulin augmentation of 17α-hydroxylase activity is mediated by phosphatidyl inositol 3-kinase but not extracellular signal-regulated kinase-1/2 in human ovarian theca cells. Endocrinology 145:175-183
28. Nestler JE, Jakubowicz DJ 1996 Decreases in ovarian cytochrome p450c17α activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 335:617-623
29. Yilmaz M, Biri A, Karkoc A, Törüner F, Bingöl B, Cakir N, Tiras B, Ayvaz G, Arslan M 2005 The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome. J Endocrinol Invest 28:1003-1008
30. Stout DL, Fugate SE 2005 Thiazolidinediones for treatment of polycystic ovary syndrome. Pharmacotherapy 25:244-252
31. la Marca A, Egbe TO, Morgante G, Paglia T, Cianci A, De Leo V 2000 Metformin treatment reduces ovarian cytochrome P-450c17α response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome. Hum Reprod 15:21-23
32. Glintborg D, Hermann AP, Andersen M, Hagen C, Beck-Nielsen H, Veldhuis JD, Henriksen JE 2006 Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome. Fertil Steril 86:385-397
33. Mehta RV, Patel KS, Coffler MS, Dahan MH, Yoo RY, Archer JS, Malcom PJ, Chang RJ 2005 Luteinizing hormone secretion is not influenced by insulin infusion in women with polycystic ovary syndrome despite improved insulin sensitivity during pioglitazone treatment. J Clin Endocrinol Metab 90:2136-2141
34. Lawson MA, Jain S, Sun S, Patel K, Malcolm PJ, Chang RJ 2008 Evidence for insulin suppression of baseline luteinizing hormone in women with polycystic ovarian syndrome and normal women. J Clin Endocrinol Metab 93:2089-2096